These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38526047)

  • 1. First-in-human trial evaluating safety and pharmacokinetics of AT-752, a novel nucleotide prodrug with pan-serotype activity against dengue virus.
    Zhou X-J; Lickliter J; Montrond M; Ishak L; Pietropaolo K; James D; Belanger B; Horga A; Hammond J
    Antimicrob Agents Chemother; 2024 May; 68(5):e0161523. PubMed ID: 38526047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, Tolerability, and Pharmacokinetics of JNJ-1802, a Pan-serotype Dengue Direct Antiviral Small Molecule, in a Phase 1, Double-Blind, Randomized, Dose-Escalation Study in Healthy Volunteers.
    Ackaert O; Vanhoutte F; Verpoorten N; Buelens A; Lachau-Durand S; Lammens L; Hoetelmans R; Van Loock M; Herrera-Taracena G
    Clin Infect Dis; 2023 Sep; 77(6):857-865. PubMed ID: 37161721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human bronchopulmonary disposition and plasma pharmacokinetics of oral bemnifosbuvir (AT-527), an experimental guanosine nucleotide prodrug for COVID-19.
    Zhou XJ; Horga A; Puri A; Winchester L; Montrond M; Pietropaolo K; Belanger B; Fletcher CV; Hammond J
    J Antimicrob Chemother; 2024 Jun; 79(6):1423-1431. PubMed ID: 38708557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease.
    Hey JA; Yu JY; Versavel M; Abushakra S; Kocis P; Power A; Kaplan PL; Amedio J; Tolar M
    Clin Pharmacokinet; 2018 Mar; 57(3):315-333. PubMed ID: 29063518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An observer-blind, randomised, placebo-controlled, phase 1, single ascending dose study of dengue monoclonal antibody in healthy adults in Australia.
    Gunale B; Farinola N; Kamat CD; Poonawalla CS; Pisal SS; Dhere RM; Miller C; Kulkarni PS
    Lancet Infect Dis; 2024 Jun; 24(6):639-649. PubMed ID: 38408457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, tolerability and pharmacokinetics of ASC10, a novel oral double prodrug of a broad-spectrum antiviral agent, β-d-N4-hydroxycytidine: results from a randomized, double-blind, placebo-controlled phase 1 study in Chinese healthy subjects.
    Liu J; Zhao Q; Zhai Y; Wu X; Kai J; Ruan J; Wu M; Wu M; Zhou Z; Yan Y; Wu JJ; Qiu Y
    Expert Opin Investig Drugs; 2024 Aug; 33(8):867-876. PubMed ID: 38988285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial.
    Yuen MF; Agarwal K; Gane EJ; Schwabe C; Ahn SH; Kim DJ; Lim YS; Cheng W; Sievert W; Visvanathan K; Ruby E; Liaw S; Yan R; Huang Q; Colonno R; Lopatin U
    Lancet Gastroenterol Hepatol; 2020 Feb; 5(2):152-166. PubMed ID: 31711752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
    Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
    CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, safety, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor for hepatitis C virus, following single ascending doses in healthy subjects.
    Denning J; Cornpropst M; Flach SD; Berrey MM; Symonds WT
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1201-8. PubMed ID: 23262999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I, First-in-Human, Single and Multiple Ascending Dose- and Food-Effect Studies to Assess the Safety, Tolerability and Pharmacokinetics of a Novel Anti-hepatitis B Virus Drug, Bentysrepinine (Y101), in Healthy Chinese Subjects.
    Liu X; Xue L; Zhang H; Xu Q; Zhang S; Ma S; Ding X; Liu L; Dong J; Qian L; Xia W; Jiang K; Huang C; Miao L
    Clin Drug Investig; 2020 Jun; 40(6):555-566. PubMed ID: 32277364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized single oral dose phase 1 study of safety, tolerability, and pharmacokinetics of Iminosugar UV-4 Hydrochloride (UV-4B) in healthy subjects.
    Callahan M; Treston AM; Lin G; Smith M; Kaufman B; Khaliq M; Evans DeWald L; Spurgers K; Warfield KL; Lowe P; Duchars M; Sampath A; Ramstedt U
    PLoS Negl Trop Dis; 2022 Aug; 16(8):e0010636. PubMed ID: 35939501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term monotherapy with IDX184, a liver-targeted nucleotide polymerase inhibitor, in patients with chronic hepatitis C virus infection.
    Lalezari J; Asmuth D; Casiró A; Vargas H; Lawrence S; Dubuc-Patrick G; Chen J; McCarville J; Pietropaolo K; Zhou XJ; Sullivan-Bólyai J; Mayers D
    Antimicrob Agents Chemother; 2012 Dec; 56(12):6372-8. PubMed ID: 23070151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, Tolerability, and Pharmacokinetics of the Novel Anti-influenza Agent Baloxavir Marboxil in Healthy Adults: Phase I Study Findings.
    Koshimichi H; Ishibashi T; Kawaguchi N; Sato C; Kawasaki A; Wajima T
    Clin Drug Investig; 2018 Dec; 38(12):1189-1196. PubMed ID: 30288682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase Ib Trial To Evaluate the Safety and Pharmacokinetics of Multiple Ascending Doses of Filociclovir (MBX-400, Cyclopropavir) in Healthy Volunteers.
    Rouphael NG; Hurwitz SJ; Hart M; Beck A; Anderson EJ; Deye G; Osborn B; Cai SY; Focht C; Amegashie C; Bowlin TL; Brooks J; Mulligan MJ
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31285228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind Phase I study in healthy subjects.
    Sun C; Liu H; Ouyang Z; Ding J; Zhang Q; Ma H; Xu D; Zhang Q; Zhou R; Yang M; Hu W
    Expert Opin Investig Drugs; 2024 May; 33(5):533-542. PubMed ID: 38662639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and pharmacokinetics of IDX184, a liver-targeted nucleotide polymerase inhibitor of hepatitis C virus, in healthy subjects.
    Zhou XJ; Pietropaolo K; Chen J; Khan S; Sullivan-Bólyai J; Mayers D
    Antimicrob Agents Chemother; 2011 Jan; 55(1):76-81. PubMed ID: 21060109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C.
    Roberts SK; Cooksley G; Dore GJ; Robson R; Shaw D; Berns H; Hill G; Klumpp K; Najera I; Washington C
    Hepatology; 2008 Aug; 48(2):398-406. PubMed ID: 18553458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infection.
    Sims KD; Lemm J; Eley T; Liu M; Berglind A; Sherman D; Lawitz E; Vutikullird AB; Tebas P; Gao M; Pasquinelli C; Grasela DM
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3496-503. PubMed ID: 24733462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers.
    Lin CC; Philips L; Xu C; Yeh LT
    J Clin Pharmacol; 2004 Mar; 44(3):265-75. PubMed ID: 14973309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and safety of FV-100, a novel oral anti-herpes zoster nucleoside analogue, administered in single and multiple doses to healthy young adult and elderly adult volunteers.
    Pentikis HS; Matson M; Atiee G; Boehlecke B; Hutchins JT; Patti JM; Henson GW; Morris A
    Antimicrob Agents Chemother; 2011 Jun; 55(6):2847-54. PubMed ID: 21444712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.